Exact Sciences (NASDAQ:EXAS) Given New $67.00 Price Target at Robert W. Baird

Exact Sciences (NASDAQ:EXAS) had its price objective reduced by Robert W. Baird from $70.00 to $67.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an outperform rating on the medical research company’s stock.

A number of other equities research analysts have also recently commented on the company. Sanford C. Bernstein raised their price objective on Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group cut their target price on Exact Sciences from $88.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, July 17th. Canaccord Genuity Group lifted their target price on Exact Sciences from $75.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Evercore ISI lifted their target price on Exact Sciences from $72.00 to $80.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus cut their target price on Exact Sciences from $100.00 to $82.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Exact Sciences has an average rating of “Moderate Buy” and an average target price of $75.06.

Exact Sciences Trading Down 3.3 %

Shares of EXAS stock opened at $51.48 on Wednesday. The company has a market cap of $9.53 billion, a P/E ratio of -44.00 and a beta of 1.27. The stock has a 50 day simple moving average of $66.76 and a two-hundred day simple moving average of $56.51. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.98 and a current ratio of 2.12. Exact Sciences has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The firm had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. Exact Sciences’s revenue was up 12.8% compared to the same quarter last year. Research analysts forecast that Exact Sciences will post -0.87 earnings per share for the current year.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the business’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the sale, the executive vice president now directly owns 13,687 shares in the company, valued at $958,090. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.36% of the company’s stock.

Institutional Trading of Exact Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Exact Sciences by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 17,740,092 shares of the medical research company’s stock valued at $1,225,131,000 after purchasing an additional 180,341 shares during the period. Capital World Investors grew its position in Exact Sciences by 74.4% during the first quarter. Capital World Investors now owns 13,025,313 shares of the medical research company’s stock worth $899,528,000 after buying an additional 5,557,168 shares in the last quarter. William Blair Investment Management LLC purchased a new position in Exact Sciences during the second quarter worth about $163,896,000. Champlain Investment Partners LLC grew its position in Exact Sciences by 175.3% during the first quarter. Champlain Investment Partners LLC now owns 2,258,235 shares of the medical research company’s stock worth $155,954,000 after buying an additional 1,438,010 shares in the last quarter. Finally, Armistice Capital LLC grew its position in Exact Sciences by 91.6% during the second quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company’s stock worth $59,154,000 after buying an additional 669,438 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.